Swedish based pharmaceutical development company, Kancera, has announced that unique blockers (antagonists) of the Fractalkine system have been patented, laying the foundations for the development of additional drug candidates.
Patents
Further development of a new drug candidate from this patented antagonist is estimated to take around 12 months and the company does not expect the development of the new drug candidate to affect the planned clinical Phase IIa study of KAND567.
This year, the company applied for two new patents within the Fractalkine project — the present application covering the antagonist of the Fractalkine system and a new synthesis method for the preparation of this type of future drug. The patent-pending synthesis method can be used for the production of both KAND567 and other newly patented antagonists.
The two products — KAND567 and future new drug candidate — are protected by separate patent applications and further enhance Kancera’s opportunities to commercialise the Frantalkine project in several diseases, such as cardiovascular disease, inflammation and cancer.